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Background: Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine 46 
release, which can downregulate the expression of metabolizing enzymes. This cascade 47 
affects drug concentrations in the plasma. We investigated the association between 48 
lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the values of 49 
acute phase inflammation marker C-reactive protein (CRP). 50 
Methods: LPV plasma concentrations were prospectively collected in 92 patients 51 
hospitalized at our institution. Lopinavir/ritonavir was administered 12-hourly, 52 
800/200 mg on day 1, and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 53 
mg, followed by 400 mg after 6, 24 and 48 hours. Hematological, liver, kidney, and 54 
inflammation laboratory values were analyzed on the day of drug level determination. 55 
Results: The median age of study participants was 59 (range 24–85) years, and 71% 56 
were male. The median duration from symptom onset to hospitalization and treatment 57 
initiation was 7 days (IQR 4–10) and 8 days (IQR 5–10), respectively. The median LPV 58 
trough concentration on day 3 of treatment was 26.5 μg/mL (IQR 18.9–31.5). LPV 59 
plasma concentrations positively correlated with CRP values (r=0.37, p<0.001), and 60 
were significantly lower when tocilizumab was preadministrated. No correlation was 61 
found between HCQ concentrations and CRP values.  62 
Conclusions: High LPV plasma concentrations were observed in COVID-19 patients. The 63 
ratio of calculated unbound drug fraction to published SARS-CoV-2 EC50 values 64 
indicated insufficient LPV concentrations in the lung. CRP values significantly correlated 65 
with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 66 















Clinical trials have been launched to find effective treatment against the novel 71 
coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause 72 
of the respiratory illness termed coronavirus disease 2019 (COVID-19) (1, 2). 73 
Approximately 15% of COVID-19 patients develop severe pneumonia (3). Cytokine 74 
release syndrome is an important factor for disease progression. Thus, treatment 75 
rationales for COVID-19 have focused on both antiviral activity and control of the 76 
infection-induced cytokine storm (4). Direct interaction between the 2 modalities must 77 
be evaluated, however, because infectious and inflammatory diseases have an impact on 78 
drug metabolism (5, 6). 79 
The release of inflammatory cytokines such as interleukin-6 (IL-6) activates intracellular 80 
signaling cascades, leading to the downregulation of cytochrome P450 enzymes (CYPs) 81 
(7). The decrease in expression and activity of CYPs is explained by transcriptional 82 
suppression of CYP mRNA, triggering a decrease in enzyme synthesis (5, 6). Systemic 83 
inflammation affects CYPs differently with a more pronounced decrease in CYP3A4 84 
expression followed by CYP2B6, CYP2C19, CYP2C9, CYP2D6 and CYP1A2 (5, 6, 8). 85 
Correlations have been reported between elevated C-reactive protein (CRP) values and 86 
high plasma levels of antipsychotic drugs (9) and voriconazole (10). CRP production is 87 
triggered by IL-6, and conversely, IL-6 suppression can be monitored with plasma CRP 88 
levels (11).  89 
The HIV drug lopinavir/ritonavir (LPV/r) has been repurposed for the treatment of 90 
SARS-CoV-2 (2). Recent brief reports of 8 (12), 12 (13), and 21 (14) COVID-19 patients, 91 
noted considerably higher LPV plasma concentrations than those observed in HIV 92 
patients (15). Considering the inhibition of drug metabolism by cytokine release, and the 93 
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administration of LPV/r (metabolized by CYP3A4), we had the rationale to prospectively 94 
monitor LPV plasma concentrations in our cohort of COVID-19 patients.   95 
The objective of this study was to investigate the association between CRP values and 96 
LPV plasma concentrations in COVID-19 patients. With this approach, we aimed to 97 
underscore the hypothesis that high inflammatory markers in the blood correlate with 98 
high LVP plasma concentrations. For comparison, we measured hydroxychloroquine 99 
(HCQ) concentrations, because it is characterized by a different metabolism (16). We 100 
also performed an age-stratified analysis to explore the combined effect of aging and 101 
inflammation on drug plasma levels. Finally, we discuss our LPV plasma trough 102 
concentration results in the context of calculated unbound concentrations in the lung 103 
compartment and published 50% effective concentrations (EC50) values for SARS-CoV-104 
2.  105 
 106 
Methods 107 
All adults (≥18 years) hospitalized at the University Hospital in Basel between 25 108 
February and 30 April 2020 for a COVID-19 infection (confirmed by real-time reverse 109 
transcriptase-polymerase chain reaction [RT-PCR] from nasopharyngeal swab 110 
specimens) were screened for study eligibility. The study was part of a COVID-19 cohort 111 
consortium investigation and approved by the northwest/central Switzerland Ethics 112 
Committee (EKNZ 2020-00769). 113 
Study population: COVID-19 patients were eligible, if they were treated with LPV/r. 114 
Patients were excluded if LPV drug concentrations were not measured. Prior to 115 
administration of LPV/r and HCQ, all concomitant drugs were reviewed for potential 116 
drug-drug interactions (DDI) via a website incorporated in our institutional treatment 117 
recommendations (17). Concomitant intake of CYP3A4 inhibitors or inducers was 118 
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stopped or switched to another compound with similar therapeutic effect. 119 
Corticosteroids were not administered, except in 3 individuals in whom a low-dose long-120 
term treatment with prednisone was continued (5 mg/d in 2 patients, 10 mg/d in 1 121 
patient). Other drugs affecting inflammation were not administered, with the exception 122 
of tocilizumab (TCZ).  123 
Treatment concepts for COVID-19 and dosing rationale: Our institutional treatment 124 
recommendations include the administration of LPV/r and HCQ for hospitalized 125 
patients. To achieve rapidly high LPV/r plasma concentrations, we administered a 126 
double dose in the first 24 hours. This approach in the early treatment phase was 127 
presumed necessary to suppress the high SARS-CoV-2 viral load in the early stage of 128 
disease (“hit early and hit hard”). The LVP/r treatment schedule included 800/200 mg 129 
twice daily on day 1, followed by a maintenance dose of 400/100 mg every 12 hours for 130 
another 4 to 6 days. LVP/r treatment was combined with HCQ for 2 days (i.e., 800 mg 131 
loading dose followed by 400 mg at 6 hours, 24 hours, and 48 hours). In patients with 132 
clinical signs and findings suggestive for COVID-19-induced hyper-inflammation, the use 133 
of TCZ was considered at the discretion of the treating COVID-19 care team. Parameters 134 
for consideration were defined in the institutional diagnostic recommendations for 135 
COVID-19. They included clinical signs (breathing frequency ≥30 per minute, O2 136 
saturation <93%), laboratory results (CRP ≥75mg/L) and the extent of radiological 137 
findings in the computed tomography scan of the lung (typical ground-glass opacities, 138 
infiltrates in ≥ 4 lobes or considerable progression of infiltrates within 24 to 48 hours). 139 
TCZ was administered intravenously at a dose of 8 mg/kg body weight, with single dose 140 
or 2 doses within 24 hours. 141 
Quantification of LPV and HCQ plasma concentrations: The institutional diagnostic 142 
recommendations for COVID-19 suggest obtaining LVP plasma trough levels on day 2 or 143 
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3 of treatment. LPV levels were quantified by using commercial calibrators and controls 144 
for liquid chromatography mass spectrometry methods (Recipe Chemicals + 145 
Instruments, Munich, Germany). The lower limit of quantification was 0.1 μg/mL.  146 
HCQ levels were measured from available plasma material obtained for LPV trough 147 
determination. HCQ was quantified with a validated liquid chromatography mass 148 
spectrometry method developed by the laboratory of clinical chemistry at the University 149 
Hospital in Zurich, Switzerland. The lower limit of quantification was 10 ng/mL. 150 
Data management, variable categorization, and statistical analysis: Patient 151 
demographics, laboratory data, vital parameters, and medication records were extracted 152 
from the electronic medical reports and the institutional Clinical Data Warehouse. 153 
Information on the time interval between onset of symptoms consistent with COVID-19 154 
and (i) hospitalization and (ii) initiation of antiviral treatment were investigated 155 
prospectively. Laboratory results obtained at the day of drug level measurement were 156 
used for this analysis. 157 
Because age-related physiological changes can affect drug pharmacokinetics (18), we 158 
categorized patients as <65 years or > 65 years. As indicated earlier, we used a tentative 159 
CRP cutoff value of 75 mg/L to aid decision making for the administration of TCZ. This 160 
CRP level was used as marker for inflammation for the analysis in the study (i.e., <75 vs 161 
> 75 mg/L).  162 
In patients receiving TCZ prior to the measurement of LPV or HCQ plasma 163 
concentrations, a time interval cutoff of 12 hours for inflammation inhibition and 164 
consecutive effect on drug metabolism was predefined. This value was chosen after 165 
consideration of various parameters (i.e., presumed time to clinical resolution of 166 
cytokine release syndrome after TCZ administration (19), dynamics of CRP levels in 167 
infections (20), drug administration schedule). Hence, in the case of TCZ administration 168 
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at ≤12 hours prior to the measurement of LPV trough levels, the interval between the 169 
two time points was considered to be too short for having an effect on LPV plasma 170 
concentrations.  171 
Absolute numbers, percentages, medians, and interquartile ranges (IQRs) were used to 172 
report demographic characteristics and laboratory results. The Mann-Whitney U test 173 
was used to compare continuous data, and the Spearman correlation coefficient to 174 
explore associations of interest. All statistical analyses were performed with GraphPad 175 
Prism and SPSS.  176 
 177 
Results 178 
Of 170 COVID-19 patients hospitalized in our institution within the study time frame, 92 179 
RT-PCR confirmed positive cases with available LPV plasma concentrations were 180 
included in the study. The median age of study participants was 59 (IQR 48–70; range 181 
24–85) years, and the majority were males (71%). The median time from onset of 182 
symptoms to hospitalization was 7 (IQR 4–10) days, and from onset of symptoms to 183 
initiation of LPV/r and HCQ treatment, was 8 (IQR 5–10) days. Twenty-seven (29%) 184 
individuals were transferred to the intensive care unit (ICU) during the hospitalization. 185 
Overall, 35 (38%) patients received TCZ, 19 (54%) prior to LPV plasma concentration 186 
measurement and 16 (46%) afterward. The median CRP values at the day of LPV plasma 187 
measurements in these TCZ groups were 88.9 (IQR 48.2-153.2) mg/L, 79.9 (IQR 48.2-188 
129.6) mg/L and 105.4 (IQR 51.9-153.7) mg/L, respectively. In 3 individuals who 189 
received TCZ before measurement of LPV plasma concentrations, the time interval 190 
between the two time points was ≤12 hours. For analysis purposes, the LPV plasma 191 
levels of these 3 patients were assigned to the group who received TCZ after drug level 192 
measurement. The CRP values in these individuals were 44.2, 124,8 and 165.8 mg/L. 193 
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Patients admitted to the ICU tended to have a higher body weight, lower albumin and 194 
hemoglobin levels, higher creatine kinase and CRP values than did patients who were 195 
not treated in the ICU (Table 1). Twenty (22%) patients presented with moderate or 196 
severe renal impairment. Table 1 shows the demographic and clinical characteristics of 197 
the patients. 198 
LPV levels and impact of inflammation: LPV trough levels (12 h + 3 hours after the last 199 
drug intake) ranged from 7.7 to 42.3 μg/mL with a median value of 26.5 (IQR 18.9–31.5) 200 
μg/L (Figure 1). LPV plasma concentrations were measured after a median time of 3 201 
(IQR 3–4) days and correlated positively with CRP values (r=0.37, p<0.001, 92 202 
observations) and leukocytes (r=0.32, p=0.002, 91 observations). When stratifying 203 
patients by predefined CRP level, we observed significantly higher LPV concentrations in 204 
patients with CRP >75 mg/L than in those with <75 mg/L (median levels: 30.7 vs 20.9 205 
μg/mL, p < 0.001) (Figure 2A). TCZ administration >12 hours prior to LPV 206 
measurement demonstrated significantly lower LPV plasma concentrations (median 207 
18.7 μg/mL) than did the comparison group (i.e., no TCZ administration or TCZ 208 
administration ≤12 hours prior to LPV measurement) (median 28.8 μg/mL, p<0.001, 209 
Figure 3). No other significant correlations were found with any other parameters listed 210 
in Table 1.   211 
Combined effect of age and inflammation on LPV concentrations: Median LPV plasma 212 
trough levels were insignificantly higher in patients who were >65 years (26.9 μg/m, n = 213 
33) than in those who were <65 years (24.5 μg/mL, n = 59) (Figure 2A). Accordingly, 214 
median LPV concentrations were not different in patients with CRP values ≥75 mg/L 215 
and who were >65 vs <65 years (median levels: 31.0 vs 30.6 μg/mL, p = 0.825) or in 216 
patients with CRP values <75 mg/L who were >65 vs <65 years (median levels: 24.7 vs 217 
20.2 μg/mL, p=0.362) (Figure 2A).  218 
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HCQ concentrations: HCQ concentrations were measured in 59 patients from available 219 
plasma samples, and ranged from 56 to 454 ng/mL with a median value of 171 (IQR 220 
128–207) ng/mL (Figure 1). In 51 plasma samples, the median time interval since the 221 
last drug intake was of 22 (range 12–31, IQR 14–23) hours, and the values showed no 222 
correlation with CRP values (r=0.044, p=0.76) or any other laboratory parameter listed 223 
in Table 1. HCQ plasma concentrations were not statistically different in patients with 224 
CRP values <75 or ≥75 mg/L (median levels: 149 versus 148 ng/mL, p=0.959) (Figure 225 
2B).  There was no correlation between LPV and HCQ plasma concentrations (r=0.197, 226 
p=0.166, n=51). 227 
 228 
Discussion 229 
Median LPV trough concentrations were an unexpected 3.5-fold higher in patients 230 
infected with SARS-CoV-2 than in HIV-infected patients, as reported historically (i.e., 7.1 231 
μg/mL) (15). Our prospective analysis on LPV plasma concentrations in 92 patients is in 232 
line with recent observations in small series that reported LPV plasma concentrations 233 
from 13 to 18 μg/mL in COVID-19 patients (12-14). The even higher trough 234 
concentrations in our study (i.e., median 26.5 μg/mL) might be explained by the double 235 
dose LPV/r dose (800/200 mg) at day 1 and the differences in the severity of COVID-19 236 
between the studies. The median CRP values available in two of the aforementioned 237 
brief reports were 13.6 mg/L (12) and 48.9 mg/L (13) vs 65 mg/L in our study. 238 
We investigated possible reasons for high LPV plasma concentrations in COVID-19 239 
patients. HCQ-mediated inhibition of the hepatic organic anion transporting polypeptide 240 
1A2 (OATP1A2) (21), and interference with liver entry and subsequent metabolic 241 
elimination is, in our view, not plausible. OATP1A2 is expressed on the apical membrane 242 
of cholangiocytes, where it reabsorbs drugs excreted into the bile (22). Inhibition of this 243 
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transporter would likely facilitate LPV/r biliary elimination. Viral-induced liver damage 244 
may cause impaired drug metabolism and high LPV plasma concentrations. However, 245 
the vast majority of individuals in our study population had only mildly elevated liver 246 
enzymes (Table 1). The effect of the double dose within the first 24 hours on LPV 247 
plasma trough concentrations measured after a median time of 3 (IQR 3-4) days is 248 
difficult to assess. LPV/r 800/200 mg single dose pharmacokinetic studies reported 249 
concentrations <12 μg/mL (23) or <14 μg/mL (24), 12 hours after intake. In a study 250 
with healthy HIV-negative volunteers, LPV trough levels ranged from 8.3 to 13.8 μg/mL 251 
at day 2 of treatment with 800/200 mg twice daily (25). In our study population, 81 252 
(88%) samples had LPV plasma levels >14 μg/mL, 66 (72%) >20 μg/mL and 35 (38%) > 253 
30 μg/mL. these data together with the LPV pharmacokinetics data in the literature (23-254 
25), noticeably suggests that the elevated LPV trough concentrations observed in 255 
COVID-19 patients cannot be explained only by the effect of the initial double dose. Our 256 
findings support the hypothesis that the systemic inflammatory response in COVID-19 257 
patients inhibits drug metabolism, leading to elevated LPV plasma concentrations. 258 
Conversely, blocking inflammation with TCZ was associated with lower LPV plasma 259 
concentrations. This is possibly explained by the fact that TCZ inhibition of inflammatory 260 
cytokines leads to a normalization of CYP metabolism.   261 
Aging is associated with physiological changes and decline of the immune function, 262 
which altogether can impact drug pharmacokinetics (18). However, LPV plasma trough 263 
concentrations were not significantly different in patients who >65 than in those who 264 
were <65 years in our study.  265 
Inflammation has been shown to have the greatest impact on CYP3A4 expression (7). 266 
This increase may, in turn, impact the magnitude of DDIs, because LPV/r inhibits 267 
CYP3A4 in a concentration-dependent manner (26). Co-administered CYP3A4 268 
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substrates can – per se – be also affected by inflammation, and can further increase the 269 
magnitude of DDIs. This interaction is illustrated by a case series of 12 patients who 270 
were followed up for direct oral anticoagulant treatment (DOAC) before and after being 271 
infected with SARS-CoV-2. LPV/r was started while DOAC was maintained at the same 272 
dose. DOAC levels after initiation of LPV/r treatment showed an average 6-fold increase 273 
(27). The co-administration of the strong CYP3A4 inhibitor ritonavir has been shown to 274 
increase rivaroxaban levels by 2.5-fold in healthy volunteers (28), whereas rivaroxaban 275 
plasma concentrations were increased by 7- up to 31-fold in COVID-19 patients treated 276 
with LPV/r (27). Notably, the disappearance of the inhibitory effect on CYP3A4 may take 277 
up to 5 days after stopping LPV/r (29).  278 
The high LPV plasma concentrations observed in COVID-19 patients inevitably raise the 279 
question about the LPV levels that can be achieved in the lung. LPV/r is thought to act by 280 
inhibiting the enzyme 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2, thereby 281 
disrupting the cleavage of the viral protein and release from the host cell (30). 282 
Coronavirus proteases, including 3CLpro, do not contain a C2-symmetric pocket, resulting 283 
in an unspecific inhibition (31). Recently, Choy et al. (32) investigated the EC50 of LPV in 284 
inhibiting SARS-CoV-2 replication in Vero E6 cells. The cells were treated with the 285 
compound for 1 hour prior to the infection by the virus at a multiplicity of infection of 286 
0.02. The authors reported EC50 values of 26.63 and 26.10 M, measuring infectious 287 
virus and viral RNA, respectively. These values correspond to in-vitro concentrations of 288 
16.7 and 16.4 μg/mL respectively (32). The antiviral activity in vivo is estimated by 289 
calculating the ratio of unbound drug concentrations achieved in the lung at the 290 
administered dose to the in vitro EC50 value (RLTEC) (33). LPV plasma measurements in 291 
12 COVID-19 patients showed median total and unbound trough concentrations of 18.0 292 
μg/mL and 0.16 μg/mL, respectively, resulting in an unbound fraction of 0.88% (13). 293 
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This fraction is consistent with the results from a previous study (34). The simultaneous 294 
determination of LPV in epithelial lining fluid (ELF) and plasma indicated an 295 
ELF/plasma ratio of 1.77 (35). Considering our total observed LPV trough plasma 296 
concentrations, the extrapolated unbound LPV trough level is 0.23 μg/mL. This value 297 
corresponds to an unbound LPV level in ELF of 0.41 μg/mL, which gives a RLTEC of 0.025. 298 
Even though the majority of the observed total LPV plasma concentrations in COVID-19 299 
patients were above the published EC50 values for SARS-CoV-2 (32), boosted LPV is 300 
unlikely to attain sufficient effective levels in the lung to inhibit the virus. In line with 301 
these arguments, current available clinical data do not demonstrate evidence for the 302 
efficacy of LPV/r for COVID-19 (36, 37). 303 
HCQ has been used historically for malaria and immune diseases. Its ability to inhibit 304 
SARS-CoV-2 is thought to be due to an increase in endosomal pH, thereby impairing the 305 
entry of the virus into the cell. HCQ also interferes with the glycosylation of cellular 306 
receptors for SARS-CoV-2, resulting in reduced virus-cell binding. Finally, HCQ has 307 
immunomodulatory activity that may suppress the cytokine storm (16). 308 
The median HCQ concentrations observed in our study (i.e., 171 ng/mL, IQR 128–207) is 309 
comparable to those reported in another study with COVID-19 patients (220 + 110 310 
ng/mL) (38), and to steady-state trough levels observed in patients with lupus 311 
erythematosus (i.e., 103–130 ng/mL)(39). Thus, the HCQ plasma concentrations in 312 
COVID-19 patients, in contrast to reported LPV plasma concentrations, were not higher 313 
than those previously observed in studies with other indications. Furthermore, no 314 
correlation was observed with CRP values. This difference may possibly be explained by 315 
the different metabolic pathways of HCQ and LPV/r, as inflammation affects CYPs 316 
differently (7). Furthermore, HCQ is known to have higher concentrations in tissue than 317 
in plasma (approximately 200- to 700-fold higher), resulting in a large distribution 318 
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volume and a long half-life (33). Therefore, HCQ plasma concentrations from COVID-19 319 
patients might not be suitable to reflect the effect of inflammation given that HCQ does 320 
not achieve steady-state concentrations during the short treatment course. Similar to 321 
LPV/r, HCQ was shown to have a low RLTEC (i.e., 0.11–0.34), indicating that HCQ levels 322 
achieved in vivo do not result in adequate clinical activity against SARS-CoV-2 (33). 323 
These calculations are supported by a studies failing to demonstrate a benefit of HCQ in 324 
both hospitalized patients with COVID-19 (40), and as prophylaxis after SARS-CoV-2 325 
exposure (41).  326 
Some limitations of this study should be acknowledged. We did not consider IL-6 327 
measurement as a routine diagnostic value within our COVID-19 cohort, and hence, in 328 
study. IL-6 is a central mediator of the acute-phase response and a primary determinant 329 
of hepatic production of CRP. IL-6 has many other pathophysiologic roles in humans 330 
(42) and its diagnostic value for COVID-19, in particular for non-severe cases, is 331 
unknown. The selection of cutoff of 12 hours in the case of TCZ administration prior to 332 
measurement of LPV plasma concentrations was clinically reasonable but arbitrary. 333 
However, this limitation applied to only 3 patients, and had no statistical influence on 334 
the results. 335 
In conclusion, high LPV trough plasma concentrations were observed in COVID-19 336 
patients. However, the calculated unbound concentrations in the lung indicates 337 
insufficient levels to inhibit SARS-CoV-2 replication. LPV levels correlated positively 338 
with CRP values and negatively with the preadministration of TCZ, indicating that 339 
COVID-19 related cytokine release significantly inhibits CYP3A4. Caution is advised 340 
when prescribing CYP3A4 substrates with a narrow therapeutic index to COVID-19 341 
patients because of the risk of elevated drug levels and related toxicities. 342 
 343 
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Table 1. Demographic, clinical and laboratory characteristics of the study population on 517 
the day of LPV plasma concentration measurement. 518 
Parameters All patients 
(N = 92) 
No ICU 
(N = 65) 
ICU 
(N = 27) 
Male sex, n (%) 65 (71) 44 (68) 21 (78) 
Age, years, median (range) 59 (24-85) 59 (24-85) 60 (32-85) 
Weight, kg (IQR) (n = 83) 84 (70-94) 81 (70-92) 90 (84-100) 
Time from symptom onset to 
hospitalization, day  
7 (4-10) 7 (4-9) 8 (5-11) 
Time from symptom onset to LPV/r 
+ HCQ treatment, day  
8 (5-10) 8 (5-10) 8 (6-11) 
Time from hospitalization to LPV/r 
+ HCQ treatment, day 
0 (0-1) 1 (0-1) 0 (0-1) 
Albumin, g/L (n = 84) 28 (24-31) 29 (26-32) 24 (21-28) 






Leukocytes, 109/L (n = 91) 5.3 (4.3-7.2) 5.3 (4.3-7.2) 5.4 (4.2-7.6) 






ASAT, U/L (n = 90) 43 (28-57) 36 (26-54) 51 (43-69) 
ALAT, U/L (n = 90) 37 (23-52) 37 (21-53) 37 (30-48) 
Alkaline phosphatase, IU/L (n = 87) 61 (48-74) 62 (49-74) 57 (44-76) 
GGT, U/L (n = 87) 55 (34-94) 54 (32-92) 63 (38-121) 
Bilirubin, μmol/L (n = 87) 17 (12-22) 17 (13-22) 16 (11-21) 
Pancreatic amylase, U/L (n = 83) 38 (29-55) 35 (27-48) 45 (36-108) 
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eGFR, mL/min/1.73 m2 (n = 92) 81 (64-97) 81 (65-97) 84 (57-98) 
Creatine kinase, U/L (n = 84) 106 (57-226) 88 (54-154) 209 (78-547) 
CRP, mg/L (n = 92) 65 (36-113) 53 (28-102) 89 (57-139) 
Systolic blood pressure, mmHg (n = 
91) 
112 (99-121) 114 (105-
124) 
93 (84-118) 
Pulse, beats/min (n = 91) 66 (60-73) 67 (61-73) 62 (55-69) 






Pulse oximetry, % (n = 91)  92 (90-94) 92 (90-94) 90 (87-92) 
Variables are median and interquartile range (IQR) unless stated otherwise. Laboratory 519 
values were not available for all patients. The number of patients with measurements is 520 
indicated for each separate laboratory parameter. 521 
ASAT = aspartate aminotransferase, ALAT = alanine aminotransferase, CRP = C-reactive 522 
protein, eGFR = estimated glomerular filtration (using CKD-EPI formula), GGT = gamma-523 
glutamyl transferase, HCQ = hydroxychloroquine, ICU = intensive care unit, LPV/r = 524 
lopinavir/ritonavir.  525 
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Figure 1. Lopinavir (n = 92) and hydroxychloroquine (n = 59) plasma 526 
concentrations in COVID-19 patients 527 
 528 
 529 
The medial Lopinavir plasma concentration was 26.5 (IQR 18.9–31.5) μg/mL. The 530 
median Hydroxychloroquine plasma concentration was 171 (IQR, 128–207) ng/mL. The 531 
dashed line represents the historical lopinavir trough level observed in HIV-infected 532 
individuals treated with lopinavir/ritonavir 400/100 mg twice daily (i.e., 7.1 μg/mL) 533 
(15). 534 
  535 
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Figure 2. Box plots (showing the 5th, 25th, 50th 75th and 95th percentiles) of lopinavir 536 
trough concentrations by CRP values in all patients and by age group (A) and box plots 537 
of hydroxychloroquine concentrations by CRP values for COVID-19 patients with trough 538 
















CRP = C-reactive protein. The dashed line represents the historical lopinavir trough level 544 
observed in HIV-infected individuals treated with lopinavir/ritonavir 400/100 mg twice 545 
daily (i.e., 7.1 μg/mL) (15).  546 
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Figure 3. Box plots (showing the 5th, 25th, 50th 75th and 95th percentiles) of lopinavir 547 
plasma trough concentrations in COVID-19 patients by administration of tocilizumab.  548 
 549 
The left bar includes LPV plasma levels from COVID-19 patients with no TCZ 550 
administration (n = 57) or TCZ administration < 12 hours prior to LPV measurement (n 551 
= 19), (median 28.8 µg/mL). The right bar represents LPV samples from COVID-19 552 
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